Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label study of NOX-A12 plus bendamustine + rituximab in relapsed chronic lymphocytic leukemia
2011-004672-11Phase 2Completed
- Sponsor
- TME Pharma
- Start
- Nov 2011
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaptesed pegol in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by TME Pharma. Primary endpoint: Safety and tolerability. Started Nov 2011; status: completed.
02
Drugs
olaptesed pegol
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-004672-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004672-11.